Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer.
Bottom Line: Our recent studies of the microRNA (miRNA) expression signature in prostate cancer (PCa) indicated that miRNA-218 (miR-218) was significantly downregulated in clinical specimens, suggesting that miR-218 might act as a tumor-suppressive miRNA in PCa.LASP1 is a cytoskeletal scaffold protein that plays critical roles in cytoskeletal organization and cell migration.Our data on pathways regulated by tumor-suppressive miR-218 provide new insight into the potential mechanisms of PCa oncogenesis and metastasis.
Affiliation: Department of Functional Genomics, Chiba, Japan; Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.Show MeSH
Related in: MedlinePlus
Mentions: To validate our past miRNA profiling results, we evaluated the expression levels of miR-218 in 17 radical prostatectomy specimens. Quantitative stem-loop RT-PCR demonstrated that miR-218 expression was significantly lower in clinical PCa specimens and PCa cell lines (PC3 and DU145) compared with non-cancerous specimens (Fig. 1). The typical FFPE specimens used for expression analysis in this study are shown in Fig. S1.
Affiliation: Department of Functional Genomics, Chiba, Japan; Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.